2 documents found, page 1 of 1
Expression of HLA-DR in Cytotoxic T Lymphocytes: A Validated Predictive Biomark...
Saraiva, DP; Azeredo-Lopes, S; Antunes, A; Salvador, R; Borralho, P; Assis, B; Pereira, IL; Seabra, Z; Negreiros, I; Jacinto, A; Braga, S; Cabral, MGNeoadjuvant chemotherapy (NACT) is common in breast cancer (BC) treatment, though more than half of the patients lack an effective response. Therefore, new predictive biomarkers and alternative therapies are crucial. Previously, we proposed HLA-DR-expressing cytotoxic T lymphocytes (CTLs) as a potential biomarker of the response to NACT. To validate this observation and further investigate these cells, 202 BC p...
HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to ...
Saraiva, DP; Jacinto, A; Borralho, P; Braga, S; Cabral, MGPrediction of breast cancer response to Neoadjuvant Chemotherapy (NACT) is an urgent need to promptly direct non-responder patients to alternative therapies. Infiltrating T lymphocytes, namely cytotoxic T lymphocytes (CTLs) have been appointed as predictors of response. However, cancer cells have the ability to dampen CTLs' activity and thus, the prognostic value of the CTLs, per se, is debatable. Here, we disc...